Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2016–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $150642 | $2M | $2M | $6M | $26M | $17M | $12M | — | — | — |
| Enterprise Value | $-353547 | $1M | $2M | $9M | $24M | $23M | $20M | — | — | — |
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.09 | 27.67 | 0.47 | 0.35 | 1.79 | 1.32 | 0.77 | — | — | — |
| P/B Ratio | — | — | — | 1.21 | 1.43 | 2.16 | 1.47 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 20.67 | 0.43 | 0.56 | 1.70 | 1.82 | 1.30 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -323.7% | -323.7% | 74.1% | 90.7% | 88.7% | 87.3% | 83.2% | 86.1% | 92.0% | 71.6% |
| Operating Margin | -7804.7% | -7804.7% | -56.6% | -45.2% | -69.2% | -50.9% | -40.9% | -53.0% | -116.4% | -1460.3% |
| Net Profit Margin | -12554.9% | -12554.9% | -181.2% | -113.1% | -73.3% | -43.4% | -46.0% | -45.6% | -7.3% | -2538.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -483.2% | -162.0% | -81.8% | -70.7% | -347.1% | — | -9.4% | -36.3% |
| ROA | -661.9% | -661.9% | -154.1% | -95.6% | -44.9% | -27.7% | -44.1% | -49.4% | -4.0% | -23.8% |
| ROIC | — | — | -62.4% | -44.3% | -48.0% | -32.4% | -54.3% | -275.4% | -92.9% | — |
| ROCE | — | — | -150.9% | -54.4% | -55.1% | -46.4% | -106.7% | — | -77.7% | -14.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.89 | 0.33 | 1.17 | 1.06 | — | 4.43 | 0.48 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | 0.73 | -0.07 | 0.83 | 1.01 | — | 3.69 | -0.36 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.29 | -8.29 | -50.82 | -3752.49 | -19.91 | -8.84 | -6.74 | -23.61 | -32.76 | — |
Net cash position: cash ($504189) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.09 | 0.09 | 0.60 | 1.68 | 1.84 | 0.80 | 0.42 | 0.05 | 1.50 | 31.35 |
| Quick Ratio | 0.09 | 0.09 | 0.60 | 1.65 | 1.80 | 0.80 | 0.37 | 0.05 | 1.50 | 31.35 |
| Cash Ratio | 0.06 | 0.06 | 0.12 | 0.12 | 1.44 | 0.44 | 0.06 | 0.01 | 0.27 | 17.15 |
| Asset Turnover | — | 0.05 | 4.54 | 1.46 | 0.53 | 0.65 | 0.74 | 0.61 | 0.61 | 0.01 |
| Inventory Turnover | — | — | — | 7.69 | 8.50 | — | 8.14 | — | — | — |
| Days Sales Outstanding | — | 142.00 | 51.34 | 64.97 | 30.68 | 43.05 | 30.36 | 16.54 | 65.00 | 7324.33 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 62.8% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 100.0% | 62.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $1M | $942462 | $751723 | $368338 | $258454 | $241434 | $150397 | $149017 |
Imminent insolvency and liquidation
As reported in financial statements, the company's gross margin has consistently remained in negative territory, reaching levels as low as -116.8% in recent periods, which underscores a fundamental inability to cover the direct costs of maintaining its clinical facilities and professional medical staffing requirements.
The persistent negative gross and operating margins indicate that the company's core service model is no longer economically viable. This suggests that the fixed costs associated with legacy clinical operations are far exceeding the minimal revenue generated, rendering the current business structure unsustainable.
Based on EDBL's reported figures, the asset turnover ratio has collapsed to near-zero levels, reflecting a total cessation of productive clinical activity that renders traditional working capital metrics like the cash conversion cycle largely irrelevant for assessing ongoing operational health.
The extreme volatility in days payable outstanding, which reached 3,706 days in 2025Q2, suggests that the company is likely deferring payments to creditors as a survival mechanism. Investors should monitor this as a sign of severe liquidity stress rather than an indicator of efficient supplier leverage.
According to recent SEC filings, the current ratio has deteriorated to a precarious 0.02, reflecting a severe liquidity crisis where cash reserves are insufficient to cover the company's immediate obligations, leaving virtually no buffer against further operational shocks or creditor demands.
The current ratio of 0.02 indicates that the company lacks the liquid assets necessary to meet its short-term liabilities. This suggests that the firm is in a state of extreme financial distress, with little to no capacity to absorb further losses or fund a potential pivot.
As indicated by market data, the P/S ratio of 2.52 and negative P/E multiples suggest that the market is pricing the company as a distressed asset rather than a functioning business, with valuation metrics failing to provide meaningful insight into future earnings potential.
Traditional valuation multiples are largely inapplicable given the near-total collapse of the revenue base and the absence of positive earnings. The current market pricing appears to reflect a speculative bet on a potential reverse merger or liquidation value rather than fundamental business performance.
Analysts frequently misapply the Price-to-Sales ratio to this business model, which obscures the fact that the current revenue base is likely residual and non-recurring, failing to account for the massive underlying liabilities that make the company's enterprise value effectively negative.
Using revenue multiples for a company in terminal decline ignores the reality that the firm's primary value driver is its remaining cash and potential tax assets, not its top-line performance. Investors should instead focus on the liquidation value of remaining assets net of all outstanding lease and legal liabilities.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BACK stock.
IMAC Holdings, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, IMAC Holdings, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
IMAC Holdings, Inc.'s current dividend yield is 100.00%.
IMAC Holdings, Inc. has -323.7% gross margin and -7804.7% operating margin.